BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Dec 19, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Anturol oxybutynin gel 3% regulatory update

FDA approved an NDA from Antares for Anturol oxybutynin gel 3% to treat overactive bladder (OAB) with symptoms of urge urinary incontinence,...

Read the full 87 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >